Search Results - "Renzo, Maria Flavia Di"

Refine Results
  1. 1

    ERα as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells by Cardamone, Maria Dafne, Bardella, Chiara, Gutierrez, Arantxa, Di Croce, Luciano, Rosenfeld, Michael G, Di Renzo, Maria Flavia, De Bortoli, Michele

    “…Estrogen receptor α (ERα) and E-cadherin are primary markers of luminal epithelial breast cancer cells with E-cadherin being a main caretaker of the epithelial…”
    Get full text
    Journal Article
  2. 2

    Sparsely-connected autoencoder (SCA) for single cell RNAseq data mining by Alessandri, Luca, Cordero, Francesca, Beccuti, Marco, Licheri, Nicola, Arigoni, Maddalena, Olivero, Martina, Di Renzo, Maria Flavia, Sapino, Anna, Calogero, Raffaele

    Published in NPJ systems biology and applications (05-01-2021)
    “…Single-cell RNA sequencing (scRNAseq) is an essential tool to investigate cellular heterogeneity. Thus, it would be of great interest being able to disclose…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Overexpression of the RON gene in human breast carcinoma by MAGGIORA, P, MARCHIO', S, STELLA, M. C, GIAI, M, BELFIORE, A, DE BORTOLI, M, DI RENZO, M. F, COSTANTINO, A, SISMONDI, P, COMOGLIO, P. M

    Published in Oncogene (04-06-1998)
    “…Constitutive activation of the RON gene, known to code for the tyrosine-kinase receptor for Macrophage Stimulating Protein (also known as Scatter Factor 2),…”
    Get full text
    Journal Article
  5. 5

    The integrin-linked kinase-associated phosphatase (ILKAP) is a regulatory hub of ovarian cancer cell susceptibility to platinum drugs by Lorenzato, Annalisa, Torchiaro, Erica, Olivero, Martina, Di Renzo, Maria Flavia

    Published in European journal of cancer (1990) (01-06-2016)
    “…Abstract Background Platinum drugs are the most powerful chemotherapeutic agents in the treatment of ovarian cancer. We demonstrated previously that…”
    Get full text
    Journal Article
  6. 6

    Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition by D'Ambrosio, Concetta, Erriquez, Jessica, Capellero, Sonia, Cignetto, Simona, Alvaro, Maria, Ciamporcero, Eric, Di Renzo, Maria Flavia, Perera, Timothy, Valabrega, Giorgio, Olivero, Martina

    “…The oncogene encodes a tyrosine kinase (TK) receptor. Its activation protects cells from death but also stimulates DNA damage response by triggering excess…”
    Get full text
    Journal Article
  7. 7

    HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor by Pavan, Simona, Musiani, Daniele, Torchiaro, Erica, Migliardi, Giorgia, Gai, Marta, Cunto, Ferdinando, Erriquez, Jessica, Olivero, Martina, Renzo, Maria Flavia

    Published in International journal of cancer (15-03-2014)
    “…The hepatocyte growth factor (HGF) also known as scatter factor activates cancer cell invasion and metastasis. We show that in ovarian cancer cells HGF induced…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    Caveolin-1 reduces osteosarcoma metastases by inhibiting c-src activity and met signaling by CANTIANI, Lara, MANARA, Maria Cristina, PICCI, Piero, SCOTLANDI, Katia, ZUCCHINI, Cinzia, DE SANCTIS, Paola, ZUNTINI, Monia, VALVASSORI, Luisa, SERRA, Massimo, OLIVERO, Martina, DI RENZO, Maria Flavia, COLOMBO, Mario Paolo

    Published in Cancer research (Chicago, Ill.) (15-08-2007)
    “…Caveolin-1 (Cav-1) is highly expressed in normal osteoblasts. This article reports that Cav-1 down-regulation is part of osteoblast transformation and…”
    Get full text
    Journal Article
  13. 13

    Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer by Erriquez, Jessica, Olivero, Martina, Mittica, Gloria, Scalzo, Maria Stella, Vaira, Marco, De Simone, Michele, Ponzone, Riccardo, Katsaros, Dionyssios, Aglietta, Massimo, Calogero, Raffaele, Di Renzo, Maria Flavia, Valabrega, Giorgio

    Published in Oncotarget (03-05-2016)
    “…Platinum-based chemotherapy is the recommended first-line treatment for high-grade serous (HGS) epithelial ovarian cancer (EOC). However, most patients relapse…”
    Get full text
    Journal Article
  14. 14
  15. 15

    Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer by DE MARIA, Raffaella, OLIVERO, Martina, IUSSICH, Selina, NAKAICHI, Munekazu, MURATA, Tomoaki, BIOLATTI, Bartolomeo, DI RENZO, Maria Flavia

    Published in Cancer research (Chicago, Ill.) (01-02-2005)
    “…Companion animal spontaneous tumors are suitable models for human cancer, primarily because both animal population and the tumors are genetically…”
    Get full text
    Journal Article
  16. 16

    A mouse model of pulmonary metastasis from spontaneous osteosarcoma monitored in vivo by Luciferase imaging by Miretti, Silvia, Roato, Ilaria, Taulli, Riccardo, Ponzetto, Carola, Cilli, Michele, Olivero, Martina, Di Renzo, Maria Flavia, Godio, Laura, Albini, Adriana, Buracco, Paolo, Ferracini, Riccardo

    Published in PloS one (19-03-2008)
    “…Osteosarcoma (OSA) is lethal when metastatic after chemotherapy and/or surgical treatment. Thus animal models are necessary to study the OSA metastatic spread…”
    Get full text
    Journal Article
  17. 17

    The Therapeutic Potential of Hepatocyte Growth Factor to Sensitize Ovarian Cancer Cells to Cisplatin and Paclitaxel In vivo by BARDELLA, Chiara, DETTORI, Daniela, OLIVERO, Martina, COLTELLA, Nadia, MAZZONE, Massimiliano, DI RENZO, Maria Flavia

    Published in Clinical cancer research (01-04-2007)
    “…Purpose: Advanced ovarian cancers are initially responsive to combinatorial chemotherapy with platinum drugs and taxanes but, in most cases, develop drug…”
    Get full text
    Journal Article
  18. 18

    The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness by Maggiora, Piera, Lorenzato, Annalisa, Fracchioli, Stefano, Costa, Barbara, Castagnaro, Massimo, Arisio, Riccardo, Katsaros, Dionyssios, Massobrio, Marco, Comoglio, Paolo M, Flavia Di Renzo, Maria

    Published in Experimental cell research (15-08-2003)
    “…RON is a member of the receptor tyrosine kinase gene family that includes the MET oncogene, whose germline mutations have been causally related to human…”
    Get full text
    Journal Article
  19. 19

    Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression by BARDELLA, Chiara, COSTA, Barbara, MAGGIORA, Piera, PATANE, Salvatore, OLIVERO, Martina, RANZANI, Guglielmina N, DE BORTOLI, Michele, COMOGLIO, Paolo M, DI RENZO, Maria Flavia

    Published in Cancer research (Chicago, Ill.) (01-08-2004)
    “…RON is a tyrosine kinase receptor that triggers scattering of normal cells and invasive growth of cancer cells on ligand binding. We identified a short RON…”
    Get full text
    Journal Article
  20. 20

    A cancer‐predisposing “hot spot” mutation of the fumarase gene creates a dominant negative protein by Lorenzato, Annalisa, Olivero, Martina, Perro, Mario, Brière, Jean Jacques, Rustin, Pierre, Renzo, Maria Flavia Di

    Published in International journal of cancer (15-02-2008)
    “…The Fumarase (Fumarate Hydratase, FH) is a tumor suppressor gene whose germline heterozygous mutations predispose to hereditary leiomyomatosis and renal cell…”
    Get full text
    Journal Article